Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Discovery of New Antagonists for TRPM8 Channel by High Throughput Assay

  • Torre Martínez, Roberto de la
  • Quirce, Susana
  • Fernández-Carvajal, M.
  • Aranda, M. Teresa
  • Pérez-Faginas, Paula
  • Infantes, Lourdes
  • Pérez de Vega, M. Jesús
  • Martín-Martínez, Mercedes
  • García-López, M. Teresa
  • González-Ros, José M.
  • Ferrer-Montiel, Antonio
  • González-Muñiz, Rosario
Trabajo presentado en el IV RECI: New Horizons in Ion Channel Research, celebrado en Cuenca (España) del 12 al 13 de febrero de 2013., TRP ion channels family is represented by 85 members that can be organized by their sequence homology into seven subfamilies. Some members of these subfamilies play an important role in detecting temperature changes. Within TRPV (vanilloid) subfamily, TRPV1 is the most studied member, and has been related with chronic pain, furthermore its pharmacological blockade and genetic deletion experiments have validated TRPV1 as a therapeutic target. Another member of the TRP family is TRPA1, which is activated by noxious cold and chemical compounds including allyl isothiocyanate (AITC), the pungent principle of wasabi and other mustard oils. TRPA1 appears to have a central role in the pain response but also it has been demonstrated that is essential for asthma [1]. TRP melastatin 8 (TRPM8) is activated by chemical cooling agents (such as menthol) or by temperatures between 28-15 ºC, mediating the detection of innocuous cold thermal stimuli. TRPM8 expression up-regulates has been suggested to play an important role in carcinogenesis and related with prostate cancer [2]. In this study was evaluated the biological activity of a new chemical library, through high throughput screening. We report here the identification of compounds presented a high blockade activity on TRPM8 and share common structure. These hits with notorious antagonistic effect were selected and observed in patch-clamp experiments performed in stable cell lines that expressed TRPV1, TRPM8 and TRPA1 to characterize more accurately their properties. These new pharmacophoric scaffolds can be used as a hit to develop new compounds with better modulator properties interesting to the clinical field or as a research tool., Supported by Consolider-Ingenio 2010 (CSD2008-00005), MICINN (BFU2009- 08346), MICCIN (BES-2010-037112), La Fundacion La Marato de TV3, PrometeoGVA and SAF2009-09323, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Generation of Molecular Diversity from Amino Acids. A Source for the Discovery of New TRP Channel Modulators

  • Aranda, M. Teresa
  • Pérez-Faginas, Paula
  • Quirce, Susana
  • Torre Martínez, Roberto de la
  • Fernández-Carvajal, Asia
  • Infantes, Lourdes
  • Pérez de Vega, M. Jesús
  • Martín-Martínez, Mercedes
  • García-López, M. Teresa
  • González-Ros, José M.
  • Ferrer-Montiel, Antonio
  • González-Muñiz, Rosario
Trabajo presentado en el IV RECI: New Horizons in Ion Channel Research, celebrado en Cuenca (España) del 12 al 13 de febrero de 2013., Ion channels are central and challenging targets in medicinal chemistry but, because of the scarce structural knowledge, rational approaches to ion channel modulators are still rare. Moreover, the multimodal activation of some channels, like TRPs, complicates still more the scenario for rational discovery programs. Due to these facts, most strategies directed to identify ion channel modulators rely on the screening of peptide and small-molecule libraries. In this context, we have been involved in the development of synthetic pathways for the generation of diverse, chiral, highly functionalized linear and heterocyclic scaffolds from amino acids, and in the production of discrete libraries from them. The screening of these libraries on different TRP channels has allowed the discovery of some innovative hits that have progressed to hit-to-lead optimization programs. This communication will deal with the synthesis, structural characterization, and biological evaluation of a collection of β,γ–diaminoester derivatives that display significant activity at TRPV1, TRPM8 and TRPA1 channels. Compound RGM04-7, a selective., Supported by MICINN grants: Consolider-Ingenio 2010 (CSD2008-00005 and CSD2006-00015), SAF2009-09323 and BFU2009-08346, and the Generalitat Valenciana (PROMETEO/2010/046).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Design, synthesis and biological evaluation of peptidomimetic ureas analogues of the thrombin receptor PAR1 antagonist RWJ-58259

  • Ventosa-Andrés, Pilar
  • García-López, M. Teresa
  • Pappos, Ioannis
  • Tsopanoglou, Nikos E.
  • Herranz, Rosario
Trabajo presentado en el XVI Congress SEQT: From a classical to a new age in medicinal chemistry, celebrado en Valencia (España) del 18 al 21 de septiembre de 2011., Thrombin regulates multiple cellular responses, such as platelet aggregation and tumor cell proliferation and angiogenesis. These cellular effects of thrombin are mediated by the activation of the protease-activated receptor PAR1. This activation unveils at the N-terminal exodomain of PAR1 the tethered activation ligand SFLLRN. First potent PAR1 antagonists were SFLLRN-based peptidomimetic ureas, represented by RWJ-58259 (Figure), which was the first antagonist that provided in vivo proof of the clinical utility of PAR1 antagonists in cardiovascular and tumoral diseases. Taking into account these precedents and recent structural studies on the thrombin/PAR1 interaction,3 a small and directed library of RWJ-58259 analogue ureas of general formula 1 has been design, synthesized and screened as PAR1 antagonists., This work was supported by the Spanish Ministry of Science and Innovation grants SAF2006-01205 and SAF2009-09323. P. V.-A. holds a FPI fellowship from the Spanish Ministry of Science and Innovation.